التفاصيل البيبلوغرافية
| العنوان: |
Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. |
| المؤلفون: |
Hsu, Melinda L, Murray, Joseph C, Psoter, Kevin J, Zhang, Jiajia, Barasa, Durrant, Brahmer, Julie R, Ettinger, David S, Forde, Patrick M, Hann, Christine L, Lam, Vincent K, Levy, Benjamin, Marrone, Kristen A, Patel, Tricia, Peterson, Valerie, Sagorsky, Sarah, Turner, Michelle, Anagnostou, Valsamo, Naidoo, Jarushka, Feliciano, Josephine L |
| المصدر: |
Oncologist; Nov2022, Vol. 27 Issue 11, p971-981, 11p, 1 Diagram, 3 Charts, 2 Graphs |
| مصطلحات موضوعية: |
DRUG side effects, LUNG cancer, IMMUNE checkpoint inhibitors, LUNG tumors, RETROSPECTIVE studies, REGRESSION analysis, TREATMENT duration, CANCER patients, TREATMENT effectiveness, RISK assessment, DESCRIPTIVE statistics, DEMOGRAPHY, LOGISTIC regression analysis, ODDS ratio, DRUG toxicity, IMMUNOTHERAPY, SYMPTOMS |
| مستخلص: |
Introduction Anti-PD-(L)1 immune checkpoint inhibitors (ICI) improve survival in patients with advanced non-small cell lung cancer (aNSCLC). The clinical features, survival, and burden of toxicities of patients with aNSCLC alive >1 year from ICI initiation are poorly understood. Materials and Methods We defined ICI survivors as patients alive >1 year after ICI start and retrospectively reviewed demographics, treatment, and immune-related adverse events (irAEs). Long-term irAEs were defined as ongoing irAEs lasting >1 year; burden of toxicity measures were based on percentage of days a patient experienced toxicity. Using linear and logistic regression, we evaluated association between demographics and disease characteristics with burden of toxicity. Results We identified 114 ICI survivors from 317 patients with aNSCLC. Half (52%) experienced an irAE of any grade, and 23.7% developed long-term irAEs. More ICI survivors with irAES in the first year had never smoked (P =. 018) or received ICIs as frontline therapy (P =. 015). The burden of toxicity in the first year significantly correlated with the burden of toxicity afterward (ρ = 0.72; P <. 001). No patients with progressive disease had a high burden of toxicity, and they experienced 30.6% fewer days with toxicity than those with stable disease. Increased duration of therapy was associated with higher odds of experiencing toxicity. Half of ICI survivors with irAEs were still receiving treatment for unresolved irAEs at time of death or last follow-up. Conclusion Significant proportions of ICI survivors have unresolved long-term toxicities. These data support a growing need to understand long-term toxicity to optimize management of those treated with ICIs. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder